Sirolimus-associated regression of benign lymphangioendothelioma

J Am Acad Dermatol. 2014 Nov;71(5):e221-2. doi: 10.1016/j.jaad.2014.07.054. Epub 2014 Oct 15.

Authors

Katherine M Hunt¹, Jennifer L Herrmann², Aleodor A Andea³, Vlada Groysman⁴, Kathleen Beckum²

Affiliations

¹ University of Alabama School of Medicine, Birmingham, Alabama. Electronic address: mmarchio@uab.edu.
² Department of Dermatology, University of Alabama, Birmingham, Alabama.
³ Department of Pathology, University of Michigan, Ann Arbor, Michigan.
⁴ Cahaba Dermatology Skin Health Center, Birmingham, Alabama.

PMID: 25438003
DOI: 10.1016/j.jaad.2014.07.054

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Humans
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation
Lymphangioma / drug therapy*
Male
Middle Aged
Sirolimus / therapeutic use*
Skin Neoplasms / drug therapy*
Thigh

Substances

Immunosuppressive Agents
Sirolimus